[go: up one dir, main page]

UY37947A - Amidas de imidazopiridina sustituidas y su uso - Google Patents

Amidas de imidazopiridina sustituidas y su uso

Info

Publication number
UY37947A
UY37947A UY0001037947A UY37947A UY37947A UY 37947 A UY37947 A UY 37947A UY 0001037947 A UY0001037947 A UY 0001037947A UY 37947 A UY37947 A UY 37947A UY 37947 A UY37947 A UY 37947A
Authority
UY
Uruguay
Prior art keywords
diseases
prophylaxis
imidazopiridine
amidas
replaced
Prior art date
Application number
UY0001037947A
Other languages
English (en)
Inventor
Kersten Matthias Gericke Dr
Thomas Mondritzki
Mario Lobell Dr
Jan Stampfuss Dr
Daniel Meibom Dr
Karl Collins Dr
Jutta Meyer Dr
Nuria Ortega Hernandez Dr
Till Freudenberger Dr
Nina Alexandra Scheerer Dr
Kirsten Leineweber Dr
Jens Schamberger Dr
Walter Kroh
Klaus Münter Dr
Alexander Straub Dr
Frank Wunder Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37947(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of UY37947A publication Critical patent/UY37947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud se refiere a nuevas amidas de imidazopiridinas sustituidas de la fórmula (I), a procedimientos para su preparación, al uso de los mismos por sí solos o en combinación para el tratamiento y / o la profilaxis de enfermedades y al uso para la preparación de medicamentos para el tratamiento y / o la profilaxis de enfermedades, en particular para el tratamiento y / o la profilaxis de enfermedades cardiovasculares, neurológicas y del sistema nervioso central, así como enfermedades metabólicas.
UY0001037947A 2017-10-24 2018-10-24 Amidas de imidazopiridina sustituidas y su uso UY37947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24

Publications (1)

Publication Number Publication Date
UY37947A true UY37947A (es) 2019-05-31

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037947A UY37947A (es) 2017-10-24 2018-10-24 Amidas de imidazopiridina sustituidas y su uso

Country Status (27)

Country Link
US (1) US20200339567A1 (es)
EP (1) EP3700903A1 (es)
JP (1) JP2021500366A (es)
KR (1) KR20200076686A (es)
CN (1) CN111225917A (es)
AR (1) AR113790A1 (es)
AU (1) AU2018354785A1 (es)
BR (1) BR112020007967A2 (es)
CA (1) CA3084422A1 (es)
CL (1) CL2020001075A1 (es)
CO (1) CO2020004968A2 (es)
CR (1) CR20200173A (es)
CU (1) CU20200041A7 (es)
DO (1) DOP2020000072A (es)
EA (1) EA202091020A1 (es)
EC (1) ECSP20023043A (es)
IL (1) IL273954A (es)
JO (1) JOP20200073A1 (es)
MA (1) MA50440A (es)
MX (1) MX2020004190A (es)
NI (1) NI202000029A (es)
PE (1) PE20201280A1 (es)
PH (1) PH12020550472A1 (es)
SG (1) SG11202003641RA (es)
TW (1) TW201932462A (es)
UY (1) UY37947A (es)
WO (1) WO2019081353A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
IL284139B1 (en) 2018-12-20 2025-02-01 Incyte Corp Imidazopyridazine and imidazopyridine compounds and their use
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (de) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
WO2023086390A1 (en) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Methods and compositions for providing myocardial protection and treating myocardial stress and fibrosis
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2407573C (en) 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
MXPA04000615A (es) 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2010033393A1 (en) 2008-09-17 2010-03-25 Allergan, Inc. Substituted 3 -amin0- 1-0x0 or thioxo-i, 2,5,6,7, 8-hexahydr0-2, 7-naphthyridine-4-carb0nitriles as selective alpha 2b antagonists
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
PE20130683A1 (es) 2010-02-27 2013-06-20 Bayer Ip Gmbh Ariltriazolonas ligadas a bisarilo y su uso
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN103298468A (zh) * 2011-02-01 2013-09-11 协和发酵麒麟株式会社 稠环杂环衍生物
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
MY172994A (en) 2012-07-20 2019-12-18 Bayer Pharma AG Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
JP2016510010A (ja) 2013-03-01 2016-04-04 バイエル・ファルマ・アクティエンゲゼルシャフト トリフルオロメチル置換環縮合ピリミジンおよびその使用
WO2016071212A1 (en) 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
TW201932462A (zh) 2019-08-16
PH12020550472A1 (en) 2021-03-15
KR20200076686A (ko) 2020-06-29
JP2021500366A (ja) 2021-01-07
US20200339567A1 (en) 2020-10-29
CU20200041A7 (es) 2021-03-11
CL2020001075A1 (es) 2021-01-22
CA3084422A1 (en) 2019-05-02
NI202000029A (es) 2020-10-09
IL273954A (en) 2020-05-31
ECSP20023043A (es) 2020-06-30
SG11202003641RA (en) 2020-05-28
WO2019081353A1 (de) 2019-05-02
MX2020004190A (es) 2020-08-03
CN111225917A (zh) 2020-06-02
DOP2020000072A (es) 2020-08-31
AU2018354785A1 (en) 2020-04-23
BR112020007967A2 (pt) 2020-10-20
EP3700903A1 (de) 2020-09-02
CO2020004968A2 (es) 2020-05-05
PE20201280A1 (es) 2020-11-24
JOP20200073A1 (ar) 2020-04-29
EA202091020A1 (ru) 2020-07-24
MA50440A (fr) 2020-09-02
AR113790A1 (es) 2020-06-10
CR20200173A (es) 2020-06-26

Similar Documents

Publication Publication Date Title
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
CO2017011851A2 (es) Compuestos novedosos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CR20180307A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
NI201500172A (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114